SCHEMBL10324601

SCHEMBL10324601

Nc1cc(C(=O)NCc2ccccn2)ccc1Cl

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.70
HPGD P15428 4/20 0.60
RAB9A P51151 3/20 0.60
POLB P06746 2/20 0.60
ALDH1A1 P00352 2/20 0.60
NPC1 O15118 2/20 0.60
LMNA P02545 1/20 0.60
CA2 P00918 1/20 0.58
CYP1A2 P05177 3/20 0.58
CYP3A4 P08684 3/20 0.58
KMT2A Q03164 2/20 0.58
CYP2D6 P10635 2/20 0.58
CYP2C9 P11712 2/20 0.58
CYP2C19 P33261 2/20 0.58
MEN1 O00255 1/20 0.56
MAPK14 Q16539 1/20 0.56
PRNP P04156 1/20 0.56
NAMPT P43490 1/20 0.56
ADORA2A P29274 1/20 0.56
ADORA1 P30542 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10324599 0.85 KDM4E (0.67) KDM4EHPGDRAB9APOLBALDH1A1
SCHEMBL11625676 0.81 LMNA (0.74) KDM4EHPGDRAB9APOLBALDH1A1
SCHEMBL11626590 0.81 POLB (0.74) KDM4EHPGDRAB9APOLBALDH1A1
SCHEMBL13423685 0.81 RAB9A (0.73) KDM4EHPGDRAB9APOLBALDH1A1
SCHEMBL6167809 0.81 BRD4 (0.60) KDM4EHPGDRAB9APOLBALDH1A1
SCHEMBL31396771 0.80 CYP1A2 (0.65) KDM4EHPGDRAB9APOLBALDH1A1
SCHEMBL11626210 0.80 SMN1; SMN2 (0.70) KDM4EHPGDRAB9APOLBALDH1A1
SCHEMBL10318404 0.80 PPARG (0.64) KDM4EHPGDRAB9AALDH1A1NPC1
SCHEMBL18150175 0.80 HPGD (0.71) KDM4EHPGDRAB9APOLBALDH1A1
SCHEMBL13175833 0.79 KMT2A (0.66) KDM4EHPGDRAB9APOLBNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012098065-A1 PYRIDO PYRIMIDINES FOR USE AS DYRK1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2012-07-26 WO claimed
US-20120184542-A1 PYRIDO PYRIMIDINES ANDERSON KEVIN (US) 2012-07-19 US claimed
WO-2012098065-A1 PYRIDO PYRIMIDINES FOR USE AS DYRK1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2012-07-26 WO disclosed
US-20120184542-A1 PYRIDO PYRIMIDINES ANDERSON KEVIN (US) 2012-07-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120184542-A1 PYRIDO PYRIMIDINES TYMS, TYMP, DPYD KDM4E 2024/4885HPGD 750/4885RAB9A 2086/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.